MX9605023A - Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas. - Google Patents

Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.

Info

Publication number
MX9605023A
MX9605023A MX9605023A MX9605023A MX9605023A MX 9605023 A MX9605023 A MX 9605023A MX 9605023 A MX9605023 A MX 9605023A MX 9605023 A MX9605023 A MX 9605023A MX 9605023 A MX9605023 A MX 9605023A
Authority
MX
Mexico
Prior art keywords
imidazolidine
active substances
pharmaceutically active
substituted compounds
dione substituted
Prior art date
Application number
MX9605023A
Other languages
English (en)
Other versions
MXPA96005023A (es
Inventor
Oswald Zimmer
Horst Bahlke
Stephan Wnendt
Cornelia Geist
Kai Zwingenberger
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MXPA96005023A publication Critical patent/MXPA96005023A/es
Publication of MX9605023A publication Critical patent/MX9605023A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos substituidos de imidazolidin-2.4-diona, un procedimiento para su preparacion así como el uso de esos compuestos en medicamentos.
MX9605023A 1995-10-27 1996-10-22 Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas. MX9605023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19540027A DE19540027A1 (de) 1995-10-27 1995-10-27 Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
DE19540027.5 1995-10-27

Publications (2)

Publication Number Publication Date
MXPA96005023A MXPA96005023A (es) 1997-06-01
MX9605023A true MX9605023A (es) 1997-06-28

Family

ID=7775931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605023A MX9605023A (es) 1995-10-27 1996-10-22 Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.

Country Status (22)

Country Link
US (1) US6004963A (es)
EP (1) EP0770613B1 (es)
JP (1) JPH09188677A (es)
KR (1) KR100445539B1 (es)
CN (1) CN1097050C (es)
AR (1) AR004517A1 (es)
AT (1) ATE181072T1 (es)
AU (1) AU707751B2 (es)
CA (1) CA2188908A1 (es)
CO (1) CO4750655A1 (es)
DE (2) DE19540027A1 (es)
DK (1) DK0770613T3 (es)
ES (1) ES2135148T3 (es)
GR (1) GR3030558T3 (es)
HU (1) HU222120B1 (es)
IL (1) IL119488A (es)
MX (1) MX9605023A (es)
PE (1) PE20011055A1 (es)
PL (1) PL184446B1 (es)
RU (1) RU2163603C2 (es)
SI (1) SI0770613T1 (es)
ZA (1) ZA968956B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
DE19917961A1 (de) 1999-04-21 2000-10-26 Degussa Verfahren zur Herstellung von Aminosäurederivaten
WO2001007048A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
MXPA02011858A (es) * 2000-05-31 2004-07-30 Tanabe Seiyaku Co Inhibidores de adhesion de celula mediada por alfabeta2.
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AU2012241184B2 (en) * 2006-03-27 2016-01-07 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
DK2656842T3 (en) 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7649007B2 (en) * 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
US7652018B2 (en) * 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
AU2007292992B2 (en) * 2006-09-08 2013-01-10 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
EP2220050A2 (en) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
PE20110136A1 (es) * 2008-06-27 2011-03-17 Novartis Ag Compuestos organicos
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091596B1 (de) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
FR2537133A1 (fr) * 1982-12-07 1984-06-08 Rhone Poulenc Sante Nouveaux derives de la (piperazinyl-1)-5 pyrrolidine, leur preparation et les medicaments qui les contiennent
US4746669A (en) * 1985-12-23 1988-05-24 Merck & Co., Inc. Substituted thiazoles as immunoregulants
JPH02101065A (ja) * 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
JPH06501708A (ja) * 1990-11-06 1994-02-24 スミスクライン・ビーチャム・コーポレイション イミダゾリジノン化合物
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
DE19529425A1 (de) * 1995-08-10 1997-02-13 Dresden Arzneimittel Neue, antikonvulsiv wirkende Imidazolin-2,4-dione, die in 1-Stellung einen orthosubstituierten Ar(alk)yl-Rest enthalten, und Verfahren zu deren Herstellung
US7466669B2 (en) * 2003-11-14 2008-12-16 Telefonaktiebolaget Lm Ericsson (Publ) Reverse link scheduler for CDMA networks

Also Published As

Publication number Publication date
CA2188908A1 (en) 1997-04-28
HU222120B1 (hu) 2003-04-28
HUP9602932A3 (en) 1998-08-28
ATE181072T1 (de) 1999-06-15
CN1097050C (zh) 2002-12-25
ES2135148T3 (es) 1999-10-16
IL119488A0 (en) 1997-01-10
AR004517A1 (es) 1998-12-16
EP0770613A1 (de) 1997-05-02
CN1152573A (zh) 1997-06-25
IL119488A (en) 2001-01-11
SI0770613T1 (en) 1999-10-31
KR970021076A (ko) 1997-05-28
KR100445539B1 (ko) 2004-12-30
DK0770613T3 (da) 1999-12-13
AU707751B2 (en) 1999-07-22
CO4750655A1 (es) 1999-03-31
RU2163603C2 (ru) 2001-02-27
HUP9602932A2 (hu) 1998-07-28
JPH09188677A (ja) 1997-07-22
HK1010367A1 (en) 1999-06-17
PL184446B1 (pl) 2002-10-31
EP0770613B1 (de) 1999-06-09
HU9602932D0 (en) 1996-12-30
ZA968956B (en) 1997-05-29
US6004963A (en) 1999-12-21
PL316706A1 (en) 1997-04-28
DE19540027A1 (de) 1997-04-30
DE59602155D1 (de) 1999-07-15
PE20011055A1 (es) 2001-12-29
GR3030558T3 (en) 1999-10-29
AU6818196A (en) 1997-05-01

Similar Documents

Publication Publication Date Title
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
HUP9900625A3 (en) Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds
HUP9801692A3 (en) Benzimidazole compounds, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions
ZA9610650B (en) 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
HUP0002050A3 (en) Substituted imidazole compounds, process for producing them, pharmaceutical compositions containing them and their use
MY114889A (en) 1-phenyl-3-dimethylamino-propane derivatives having pharmacological activity
HUP9802259A3 (en) 1,4,5-substituted imidazole compounds, pharmaceutical compounds containing them, process for producing them and their use
ZA964337B (en) Pharmaceutical compositions containing irbesartan.
WO1996032003A3 (en) Tetrahydroimidazopyridoindolediones and their use as medicaments
NZ333588A (en) Sulphamates as anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
PL323152A1 (en) Derivatives of 1,3-propanodiole as biologically active compounds
HU9601251D0 (en) Process for the preparation of concentrated, biologically active silicon compounds
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
AU5802196A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers
ZA965712B (en) New oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds.
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
AU5801996A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
ZA961138B (en) Solid active ingredient compositions containing hydroxypropylcellulose.
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
HUP9602640A3 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
ZA968550B (en) Novel processes for the preparation of anti-malarial compounds.
ZA969319B (en) Derivatives of imidazole n-benzyldioxole, their preparation process, their use as medicaments, pharmaceutical composition and new use.